Analysis of Diagnostic and Medical Delay Data Among Lung Cancer Patients in 2019 and 2020

Author(s)

Varga JK1, Boncz I2, Grmela G1, Pápai-Székely Z1, Mátyus M1, Zsoldos G1, Kiss P1, Grassalkovich A1, Kívés Z3
1Saint George University Hospital of County Fejér, Székesfehérvár, Hungary, 2University of Pécs, Pécs, Hungary, 3University of Pécs, PÉCS, BA, Hungary

OBJECTIVES: This study aims to investigate the diagnosis and medical delay among lung cancer patients, furthermore, the involvement of the SARS-CoV-2 pandemic in diagnostic delay.

METHODS: The retrospective study was performed in Pulmonology Department at Fejer County University Teaching Hospital in Hungary, between January 1, 2019 and December 31, 2020. We analysed the data of patients with primary lung cancer and changes in the diagnostic and medical delay time (n=102). Descriptive statistical analyses were applied (mean, standard deviation, absolute and relative frequency).

RESULTS: The average age is 68 years. 44.1% of patients were admitted to the institution from lung care, 12.7% from the emergency department and 43.1% from other providers. The mean diagnostic delay was 89.8±47.9 days in the two years. The time from first appointment to the chest CT was 21.42±28.08 days. On average, 21.93±25.1 days elapsed from CT to bronchoscopy. On average 35.79±29.2 days elapsed between oncoteam consultation and initiation of treatment. For those requiring PET/CT, the total diagnostic time increased from 69.7 days to 119.6 days (p<0.001). The total diagnostic time of patients receiving chemotherapy (22.9 days) was significantly lower compared to both patients receiving surgery (50.9 days) and those receiving radiotherapy (101.3 days) (p<0.001). In 2020, the number of primary lung care appointments decreased significantly, from 58% to 31% of all primary care visits, while the proportion of primary appointments in other care settings increased significantly from 2019 to 2020, from 28% to 58% (p=0.008). No significant difference was observed in the mean of the total diagnostic delay times (p=0.273), it was 83.8±47.9 days in 2019 and then 94.7± 47.8 days.

CONCLUSIONS: Reducing the therapeutic delay – which constitutes a substantial part of the total diagnostic period, is a realistic goal and should be targeted.

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)

Code

HSD106

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×